Tags : Combination Therapy

Chugai and Takeda Collaborate to Evaluate the Combination Therapy for

Shots: Following a joint clinical research agreement between Roche and Exelixis and in conjunction with certain rights granted in Japan, Chugai and Takeda will study Tecentriq (atezolizumab) and Cabometyx (cabozantinib) as a combination therapy in Japan The three global P- III CONTACT studies are ongoing to investigate the combination of atezolizumab and cabozantinib as a […]Read More

Roche Expands its Collaboration with Immunomedics to Evaluate Tecentriq Based

Shots: The companies extend their existing collaboration to evaluate Immunomedics’ Trodelvy (sacituzumab govitecan-hziy) in combination with Tecentriq (atezolizumab) in patients with mUC and mNSCLC. The partners have ongoing collaboration in 1L metastatic triple-negative BC Roche will conduct two P-Ib/II studies utilizing MORPHEUS platform. The MORPHEUS-mUC study will evaluate Tecentriq + Trodelvy vs Tecentriq as monothx. […]Read More

Genmab Reports Results of Daratumumab Based Combination Therapy in P-III

Shots: The P-III ANDROMEDA (AMY3001) study involves assessing of Daratumumab (SC) + cyclophosphamide + bortezomib + dexamethasone (CyBorD) vs CyBorD as monothx. in 388 patients newly diagnosed with AL amyloidosis, conducted by Janssen The P-III ANDROMEDA study resulted in meeting its 1EPs of the percentage of patients with hematologic complete response (53.3% vs 18.1%), the […]Read More

Genome & Company Signs a Clinical Trial Agreement with Merck

Shots: Genome & Company enters into a clinical trial and supply agreement with Merck KGaA and Pfizer to evaluate the safety, tolerability, biological and clinical activities of GEN-001 + Bavencio (avelumab) for multiple cancer indications Genome & Company will sponsor the study while Merck KGaA will supply avelumab in P-I/Ib study which is expected to […]Read More

Henlius and Ascentage Pharma Collaborate to Evaluate the Combination Therapy

Shots: The companies collaborated to conduct the clinical studies of a dual regimen consisting of Ascentage’s APG-2575 and Henlius’s HLX01 (biosimilar, rituximab) for the treatment of chronic lymphocytic leukemia in the People’s Republic of China The teams from both the companies will explore the clinical utility of the dual regimen aiming to demonstrate a synergistic […]Read More

Janssen’s Darzalex (daratumumab) Combination Therapy Receives FDA’s Approval for Frontline

Shots: The approval is based on P-III CASSIOPEIA (MMY3006) study involve assessing of Darzalex + bortezomib, thalidomide and dexamethasone (VTd) vs VTd in 1,085 newly diagnosed patients with previously untreated symptomatic MM who are eligible for high dose CT and stem cell transplant The P-III CASSIOPEIA study is sponsored by IFM in collaboration with HOVON […]Read More

Roche Reports Results of Perjeta (pertuzumab) Fixed Dose SC Combination

Shots: The P-III FeDeriCa study involves assessing of Perjeta (pertuzumab) and Herceptin (trastuzumab) as FDC in SC formulation + CT (IV) vs its standard IV Infusion formulation + CT in patients with HER2-positive eBC, being treated with neoadjuvant and adjuvant setting The P-III FeDeriCa study results: reduction in the time spent for receiving treatment, loading […]Read More

AbbVie Signs a Research Agreement with Idera Pharmaceuticals to Evaluate

Shots: AbbVie and Idera collaborated to conduct clinical study evaluating the combination of ABBV-368 + tilsotolimod + CT or ABBV-181. AbbVie will be responsible for conducting the trial while Idera to provide clinical trial supply of tilsotolimod The P-Ib study will evaluate the safety, tolerability, PK and preliminary efficacy of ABBV-368 plus tilsotolimod in three […]Read More